GEHC gives reasons to look beyond temporary China woes and shares reverse higher
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Lost in the market's sharp rotation out of tech stocks is a really bullish call on major banks
Neuralink rival Synchron's brain implant now lets people control Apple's Vision Pro with their minds
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
We're encouraged by Abbott stock trading but discouraged by moves in Honeywell
